Trevena, Inc. (NASDAQ:TRVN) Short Interest Update

Trevena, Inc. (NASDAQ:TRVN) was the target of a large increase in short interest in August. As of August 31st, there was short interest totalling 20,100 shares, an increase of 24.1% from the August 15th total of 16,200 shares. Based on an average trading volume of 57,700 shares, the short-interest ratio is currently 0.3 days. Approximately 2.4% of the company’s stock are sold short.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on Trevena in a research note on Friday. They issued a “sell” rating for the company.

Trevena Trading Down 3.4 %

Shares of NASDAQ:TRVN traded down $0.20 during mid-day trading on Monday, reaching $5.75. The company had a trading volume of 503 shares, compared to its average volume of 25,207. The company’s 50-day moving average price is $5.05 and its 200-day moving average price is $8.37. Trevena has a one year low of $3.35 and a one year high of $25.75. The firm has a market cap of $4.89 million, a price-to-earnings ratio of -2.22 and a beta of 1.03.

Trevena (NASDAQ:TRVN) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.36. The firm had revenue of $0.33 million during the quarter. On average, research analysts anticipate that Trevena will post -32.25 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Trevena stock. Armistice Capital LLC purchased a new stake in shares of Trevena, Inc. (NASDAQ:TRVN) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 797,714 shares of the biopharmaceutical company’s stock, valued at approximately $576,000. Armistice Capital LLC owned about 4.61% of Trevena at the end of the most recent quarter. 13.56% of the stock is owned by institutional investors.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.